Bartomeu Mestre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bartomeu Mestre has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Andreu Vaquer
Multidisciplinary Sepsis Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
2 shared publications - Roberto de la Rica
Health Research Institute of the Balearic Islands, Spain
2 shared publications - Sofia Tejada
Multidisciplinary Sepsis Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
2 shared publications - Amanda Iglesias
Institut d’Investigació Sanitària Illes Balears (IdISBa), 07120 Palma de Mallorca, Spain
1 shared publication Amanda Iglesias Coma
Instituto de Investigación Sanitaria Illes Balears (IdISBa), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Palma de Mallorca, Spain
1 shared publication- Antonio Clemente
Group of Innovation in Immunopathology of Infections (GTERi), Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
1 shared publication
Latest Publications
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA3781
Phenotypic Classification of COPD Exacerbations Using Exhaled Air Biomarkers
Introduction: Exacerbations of chronic obstructive pulmonary disease (COPD) can be classified by etiology, but endotype diagnosis usually requires invasive airway sampling. This study evaluates a rapid, non‑invasive gold nanoparticle immunoassay to discriminate endotypes by detecting myeloperoxidase (MPO) and interleukin‑5 (IL‑5) in exhaled air. Methods: A prospective study included 99 stable COPD patients, 77 exacerbated COPD patients and 21 controls. Exacerbated patients underwent blood count, sputum culture, and viral PCR and were classified as eosinophilic (≥100 eosinophils/µL, negative culture and PCR, n=21), bacterial (positive culture, n=17), viral (positive PCR, n=14), or NINO (n=25). Surgical masks were analyzed using immunoassays functionalized with MPO and IL‑5 antibodies. Results: Stable COPD patients showed higher MPO and IL‑5 (MPO:96.8±6.8; IL‑5:60.1±3.6 S) than controls (MPO:72.0±7.5; IL‑5:56.3±15.1 S, p<0.0001). During exacerbation, MPO increased in all endotypes compared to stable COPD (p<0.0001), being highest in the bacterial endotype (171.4±5.1 S), followed by viral (169.8±5.4 S), eosinophilic (142.3±4.4 S), and NINO (136.7±6.3 S). IL‑5 was highest in the eosinophilic endotype (142.3±4.4 S), followed by viral (107.4±1.9 S), bacterial (73.9±1.6 S), and NINO (67.7±3.1 S), with significant differences vs. stable COPD and controls (p<0.0001). Conclusion: Non‑invasive MPO and IL‑5 detection enables accurate COPD exacerbation endotyping, supporting personalized therapy. erj;68/suppl_70/PA3781/F1 F1 F1
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA3781
Phenotypic Classification of COPD Exacerbations Using Exhaled Air Biomarkers
Introduction: Exacerbations of chronic obstructive pulmonary disease (COPD) can be classified by etiology, but endotype diagnosis usually requires invasive airway sampling. This study evaluates a rapid, non‑invasive gold nanoparticle immunoassay to discriminate endotypes by detecting myeloperoxidase (MPO) and interleukin‑5 (IL‑5) in exhaled air. Methods: A prospective study included 99 stable COPD patients, 77 exacerbated COPD patients and 21 controls. Exacerbated patients underwent blood count, sputum culture, and viral PCR and were classified as eosinophilic (≥100 eosinophils/µL, negative culture and PCR, n=21), bacterial (positive culture, n=17), viral (positive PCR, n=14), or NINO (n=25). Surgical masks were analyzed using immunoassays functionalized with MPO and IL‑5 antibodies. Results: Stable COPD patients showed higher MPO and IL‑5 (MPO:96.8±6.8; IL‑5:60.1±3.6 S) than controls (MPO:72.0±7.5; IL‑5:56.3±15.1 S, p<0.0001). During exacerbation, MPO increased in all endotypes compared to stable COPD (p<0.0001), being highest in the bacterial endotype (171.4±5.1 S), followed by viral (169.8±5.4 S), eosinophilic (142.3±4.4 S), and NINO (136.7±6.3 S). IL‑5 was highest in the eosinophilic endotype (142.3±4.4 S), followed by viral (107.4±1.9 S), bacterial (73.9±1.6 S), and NINO (67.7±3.1 S), with significant differences vs. stable COPD and controls (p<0.0001). Conclusion: Non‑invasive MPO and IL‑5 detection enables accurate COPD exacerbation endotyping, supporting personalized therapy. erj;68/suppl_70/PA3781/F1 F1 F1
- Open Access
- 19 May 2025
- Published by MDPI AG in Biosensors
- Vol. 15 (5) , 323
A Nanoparticle-Based Immunoassay on Facemasks for Evaluating Neutrophilic Airway Inflammation in COPD Patients
Patients with chronic obstructive pulmonary disease (COPD) often experience acute exacerbations characterized by elevated neutrophilic inflammation in the lungs. Currently, this condition is diagnosed through visual inspection of sputum color and volume, a method prone to personal bias and unsuitable for patients who are unable to expectorate spontaneously. In this manuscript, we present a novel approach for measuring and monitoring exhaled myeloperoxidase (MPO), a biomarker of neutrophilic airway inflammation, without the need for sputum analysis. The method involves analyzing an unmodified surgical facemask worn by the patient for 30 min using biosensing decals that transfer antibody-coated nanoparticles. These colloids specifically interact with MPO trapped by the facemask in a dose-dependent manner, enabling the quantification of MPO levels, with a dynamic range up to 3 · 101 µg·mL−1. The proposed diagnostic approach successfully differentiated patients with acute exacerbations from stable patients with 100% sensitivity and specificity. Healthy individuals also showed significantly lower MPO levels compared to COPD patients. Our results suggest that facemask analysis could be a non-invasive diagnostic tool for airway diseases, particularly in patients unable to expectorate.
- 19 May 2025
- Published by MDPI AG in Biosensors
- Vol. 15 (5) , 323
Open AccessA Nanoparticle-Based Immunoassay on Facemasks for Evaluating Neutrophilic Airway Inflammation in COPD Patients
Patients with chronic obstructive pulmonary disease (COPD) often experience acute exacerbations characterized by elevated neutrophilic inflammation in the lungs. Currently, this condition is diagnosed through visual inspection of sputum color and volume, a method prone to personal bias and unsuitable for patients who are unable to expectorate spontaneously. In this manuscript, we present a novel approach for measuring and monitoring exhaled myeloperoxidase (MPO), a biomarker of neutrophilic airway inflammation, without the need for sputum analysis. The method involves analyzing an unmodified surgical facemask worn by the patient for 30 min using biosensing decals that transfer antibody-coated nanoparticles. These colloids specifically interact with MPO trapped by the facemask in a dose-dependent manner, enabling the quantification of MPO levels, with a dynamic range up to 3 · 101 µg·mL−1. The proposed diagnostic approach successfully differentiated patients with acute exacerbations from stable patients with 100% sensitivity and specificity. Healthy individuals also showed significantly lower MPO levels compared to COPD patients. Our results suggest that facemask analysis could be a non-invasive diagnostic tool for airway diseases, particularly in patients unable to expectorate.
- Open Access
- 20 February 2025
- Published by MDPI AG in Biosensors
- Vol. 15 (3) , 129
Detecting Respiratory Pathogens for Diagnosing Lower Respiratory Tract Infections at the Point of Care: Challenges and Opportunities
Lower respiratory tract infections (LRTIs) are a leading cause of mortality worldwide, claiming millions of lives each year and imposing significant healthcare costs. Accurate detection of respiratory pathogens is essential for the effective management of LRTIs. However, this process often relies on sputum analysis, which requires extensive pretreatment steps. The viscous nature and complex composition of sputum present additional challenges, especially in settings where a rapid diagnosis at the point of care is essential. In this review, we describe the main types of LRTI, highlighting different patient care pathway and points of care. We review current methods for liquefying sputum samples and provide an overview of current commercially available diagnostic tools used in hospitals for LRTI detection. Furthermore, we critically review recent advancements in the literature focused on detecting respiratory pathogens and mechanisms of antimicrobial resistance in sputum, including nucleic acid amplification tests, immunoassays and other innovative approaches. Throughout the paper, we highlight challenges and opportunities associated with developing new biosensor technologies tailored for detecting respiratory pathogens in lower respiratory specimens. By shedding light on these pressing issues, we aim to inspire scientific community to create innovative diagnostic tools to address the urgent healthcare burden of lung diseases.
- 20 February 2025
- Published by MDPI AG in Biosensors
- Vol. 15 (3) , 129
Open AccessDetecting Respiratory Pathogens for Diagnosing Lower Respiratory Tract Infections at the Point of Care: Challenges and Opportunities
Lower respiratory tract infections (LRTIs) are a leading cause of mortality worldwide, claiming millions of lives each year and imposing significant healthcare costs. Accurate detection of respiratory pathogens is essential for the effective management of LRTIs. However, this process often relies on sputum analysis, which requires extensive pretreatment steps. The viscous nature and complex composition of sputum present additional challenges, especially in settings where a rapid diagnosis at the point of care is essential. In this review, we describe the main types of LRTI, highlighting different patient care pathway and points of care. We review current methods for liquefying sputum samples and provide an overview of current commercially available diagnostic tools used in hospitals for LRTI detection. Furthermore, we critically review recent advancements in the literature focused on detecting respiratory pathogens and mechanisms of antimicrobial resistance in sputum, including nucleic acid amplification tests, immunoassays and other innovative approaches. Throughout the paper, we highlight challenges and opportunities associated with developing new biosensor technologies tailored for detecting respiratory pathogens in lower respiratory specimens. By shedding light on these pressing issues, we aim to inspire scientific community to create innovative diagnostic tools to address the urgent healthcare burden of lung diseases.